Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 901–1,000 of 1,017
Personalized Cardiovascular Medicine Today
Blaus, A., Madabushi, R., Pacanowski, M. A., Rose, M., Schuck, R. N., Stockbridge, N., Temple, R., & Unger, E. F. (2015) · Circulation · doi:10.1161/circulationaha.114.009761 · Cited by 38
“In the case of torcetrapib, both of these problems were suggested as possible reasons for why this drug, which substantially increased blood levels of high-density lipoprotein (HDL) cholesterol, was associated with worsened cardiovascular outcomes in a large randomized trial.(31) For example, it was suggested that mer…”
BackgroundRecent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol
Wright, R. S. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362059d · Cited by 37
Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
Yamashita, S., Ruscica, M., Macchi, C., Corsini, A., Matsuzawa, Y., & Sirtori, C. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.035 · Cited by 37
Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection
Bowman, E., & Funderburg, N. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00442-9 · Cited by 44
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 38
Xue, H., & Pan, W. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009105 · Cited by 45
“On the other hand, contrary to observational studies [37], HDL cholesterol does not appear to have a causal role on CAD, as evidenced by several MR analyses and recent RCTs [31–33, 38, 39].”
Reconstituted HDL in Acute Coronary Syndromes
Chenevard, R., Hürlimann, D., Spieker, L. E., Béchir, M., Enseleit, F., Hermann, M., Flammer, A. J., Sudano, I., Corti, R., Lüscher, T. F., et al. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00221.x · Cited by 37
“The results of just recently published randomized clinical trials with the CETP-inhibitor torcetrapib, however, cast doubts about the efficacy and safety of this therapeutic principle [31–33].”
BackgroundResultQian, Y., Pu, Y., Liu, L., Wang, D. Z., Zhao, X., Wang, C., Wang, Y., Liu, G., Pan, Y., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064395 · Cited by 40
Roe, M. T., Ou, F., Alexander, K. P., Newby, L. K., Foody, J. M., Gibler, W. B., Boden, W. E., Ohman, E. M., Smith, S. C., & Peterson, E. D. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn364 · Cited by 37
Lipid transfers to HDL are predictors of precocious clinical coronary heart disease
Maranhão, R. C., Freitas, F. R., Strunz, C. M. C., Santos, R. D., Mansur, A. J., & Mansur, A. D. P. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.11.011 · Cited by 38
Qualitative characteristics of HDL in young patients of an acute myocardial infarction
Kavo, A. E., Rallidis, L. S., Sakellaropoulos, G. C., Lehr, S., Hartwig, S., Eckel, J., Bozatzi, P. I., ANASTASIOU‐NANA, M. I., Tsikrika, P., & Kypreos, K. E. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.017 · Cited by 37
Hwang, Y., Ahn, H. Y., Park, H., & Park, C. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0195 · Cited by 40
Vazzana, N., Ganci, A., Cefalu, A. B., Lattanzio, S., Noto, D., Santoro, N., Saggini, R., Puccetti, L., Averna, M. R., & Davì, G. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000063 · Cited by 41
Familial hypercholesterolaemia: cholesterol efflux and coronary disease
Versmissen, J., Vongpromek, R., Yahya, R., van der Net, J. B., der Zee, L. V. V., Blommesteijn, J., Wattimena, D. J. L., Rietveld, T., Pullinger, C. R., Christoffersen, C., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12643 · Cited by 37
Battaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36
“After excluding 86 duplicates and 238 trials not meeting the inclusion criteria, 7 RCTs were selected [1, 8, 29, 30, 31, 32, 33] in which the combination of E+another lipid-lowering drug was tested against the same lipid-lowering drug at the same dosage; these were included in the quantitative synthesis (metaanalysis).”
BackgroundCholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro
Barter, P. J., & Rye, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306879 · Cited by 36
“The effect of torcetrapib on clinical cardiovascular events was investigated in the ILLUMINATE trial that included 15 067 high-risk statin-treated people.(8) Torcetrapib increased HDL cholesterol levels by 72% and decreased LDL cholesterol levels by 25%.”
BackgroundSelf-citationObicetrapib—the Rebirth of CETP Inhibitors?
Chang, B. J., Laffin, L. J., Sarraju, A., & Nissen, S. E. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01231-5 · Cited by 39
“Understandably, this greatly reduced enthusiasm for other CETP inhibitors, but upon further examination of the torcetrapib data, the excess mortality was associated with off-target drug effects related to this drug’s unique structure rather than CETP inhibition per se [18].”
BackgroundRubinow, K. B., Vaisar, T., Tang, C., Matsumoto, A. M., Heinecke, J. W., & Page, S. T. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p026005 · Cited by 39
Lu, J. J.-Q., Hübner, K., Nanjee, M. N., Brinton, E. A., & Mazer, N. A. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003509 · Cited by 40
“However, the recent failures of a number of HDL-C raising intervention trials [5–7] have called for a reexamination of the HDL-C hypothesis.”
BackgroundKasenda, B., von Elm, E. B., You, J., Blümle, A., Tomonaga, Y., Saccilotto, R., Amstutz, A., Bengough, T., Meerpohl, J., Stegert, M., et al. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-131 · Cited by 36
“Reasons for discontinuation of RCTs include unanticipated adverse effects (harm) [1], larger than expected benefit of an intervention (early superiority) [2], or a very low probability of detecting a designated treatment effect with continued patient recruitment or follow-up (futility) [3].”
BackgroundSuico, J. G., Wang, M., Friedrich, S. W., Cannady, E. A., Konkoy, C. S., Ruotolo, G., & Krueger, K. A. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12287 · Cited by 37
“Torcetrapib, the first drug in this class, was terminated after an excess risk of mortality and CV events, and increases in blood pressure and aldosterone levels were observed in the Phase 3 ILLUMINATE trial.([5]) Increases in blood pressure and overall mineralocorticoid activity with torcetrapib have also been report…”
BackgroundLinden, F., Domschke, G., Erbel, C., Akhavanpoor, M., Katus, H. A., & Gleissner, C. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00455 · Cited by 43
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Adamski, P., Adamska, U., Ostrowska, M., Koziński, M., & Kubica, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241234 · Cited by 37
“Atherosclerotic Events (ILLUMINATE) study was early terminated due to observed 58% increased mortality and 25% increased risk of cardiovascular events in patients receiving torcetrapib [11].”
BackgroundRautureau, Y., Deschambault, V., Higgins, M., Rivas, D., Mecteau, M., Geoffroy, P., Miquel, G., Uy, K., Sánchez, R., Lavoie, V., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031134 · Cited by 37
Self-citationDai, W., Long, J., Cheng, Y., Chen, Y., & Zhao, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25835-5 · Cited by 36
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 45
Zhu, L., Luu, T. N., Emfinger, C. H., Parks, B. A., Shi, J., Trefts, E., Zeng, F., Kuklenyik, Z., Harris, R. C., Wasserman, D. H., et al. (2018) · Diabetes · doi:10.2337/db18-0474 · Cited by 40
Impact of ADCY9 Genotype on Response to Anacetrapib
Hopewell, J. C., Ibrahim, M. A.-H., Hill, M., Shaw, P. M., Braunwald, E., Blaustein, R. O., Bowman, L. J., Landray, M., Sabatine, M. S., Collins, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041546 · Cited by 37
Self-citationTeis, A., Cediel, G., Amigó, N., Julve, J., Aranyo, J. A., Andrés-Cordón, J. F., Puig-Jové, C., Castelblanco, E., Gual‐Capllonch, F., Ferrer‐Sistach, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82861-6 · Cited by 41
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B.-L. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 36
HDL cholesterol and clinical outcomes in diabetes mellitus
Ishibashi, T., Kaneko, H., Matsuoka, S., Suzuki, Y., Ueno, K., Ohno, R., Okada, A., Fujiu, K., Michihata, N., Jo, T., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad029 · Cited by 39
Plaque stabilizing effects of apolipoprotein A-IV
Geronimo, F., Barter, P. J., Rye, K., Heather, A. K., Shearston, K., & Rodgers, K. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.04.019 · Cited by 37
Self-citationDrexel, H. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00745.x · Cited by 33
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
Association of HDL cholesterol and triglycerides with mortality in patients with heart failure
de Freitas, H. F. G., Barbosa, E. A., da Rosa, F. H. F. P., Lima, A. C., & Mansur, A. J. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009000500004 · Cited by 38
Xing, Y., Cohen, A., Rothblat, G. H., Sankaranarayanan, S., Weibel, G. L., Royer, L. J., Francone, O. L., & Rainey, W. E. (2011) · Endocrinology · doi:10.1210/en.2010-1049 · Cited by 36
Low high-density lipoprotein cholesterol: current status and future strategies for management
Singh, V. N., Sharma, R., Kumar, A., & Deedwania, P. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5685 · Cited by 48
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 45
Self-citationCaveney, E. J., & Cohen, O. J. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500127 · Cited by 40
Niu, W., & Qi, Y. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000748 · Cited by 35
“However, 2 large randomized controlled trials of CETP inhibitors have failed to show any benefit for cardiovascular disease events and the progression of atherosclerosis.(3,4) Currently, whether circulating CETP is causally associated with coronary heart disease (CHD) or merely a biomarker of underlying atherosclerosi…”
BackgroundImpact of High-Density Lipoproteins on Sepsis
Geest, B. D., & Mishra, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112965 · Cited by 42
Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not
Sorci‐Thomas, M. G., & Thomas, M. J. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829d48a5 · Cited by 36
“study of the CETP inhibitor, torcetrapib, reported a 72% increase in plasma HDL-C concentration but was halted because of an increased risk of mortality and morbidity because of adverse effects of unknown etiology.(14) Studies with the CETP inhibitors evacetrapib, dalcetrapib, and anacetrapib, all of which substantial…”
BackgroundSong, G., Tian, H., Qin, S., Sun, X., Yao, S., Zong, C., Luo, Y., Liu, J., Yu, Y., Sang, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.043 · Cited by 36
“Recent years a great line of studies has been focusing on the strategies of anti-inflammatory [2] and non-high-density lipoprotein cholesterol (non-HDL-C) based therapies of atherosclerosis [3].”
BackgroundInfluentialTargeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 38
Mendelian Randomization and Estimation of Treatment Efficacy for Chronic Diseases
Schooling, C. M., Freeman, G., & Cowling, B. J. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws344 · Cited by 36
Novel concepts in HDL pharmacology
Remaley, A. T., Norata, G. D., & Catapano, A. L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu141 · Cited by 39
Elshazly, M. B., Nicholls, S. J., Nissen, S. E., John, J. S., Martin, S. S., Jones, S. R., Quispe, R., Stegman, B., Kapadia, S. R., Tuzcu, E. M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.021 · Cited by 39
Effects of obesity treatment on female reproduction: results do not match expectations
Legro, R. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.02.109 · Cited by 71
Translating Evidence of HDL and Plaque Regression
Bartolo, B. A. D., Psaltis, P. J., Bursill, C. A., & Nicholls, S. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.307026 · Cited by 39
Bashore, A. C., Liu, M., Key, C.-C. C., Boudyguina, E. Y., Wang, X., Carroll, C. M., Sawyer, J. K., Mullick, A. E., Lee, R. G., Macauley, S. L., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312382 · Cited by 39
Wijeratne, T., Menon, R., Sales, C., Karimi, L., & Crewther, S. G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4388 · Cited by 36
“The LoDoCo trial demonstrated colchicine prevented recurrent cardiovascular events in patients with stable coronary artery disease in addition to high dose statins (76-78).”
BackgroundChen, H., Tsai, W., Chiu, Y., Hsu, S., Pai, M., Yang, J., & Peng, Y. (2015) · Medicine · doi:10.1097/md.0000000000000619 · Cited by 34
The HALTS Trial — Halting Atherosclerosis or Halted Too Early?
Blumenthal, R. S., & Michos, E. D. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908838 · Cited by 34
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 36
Jorge, I., Burillo, E., Mesa, R., Baila-Rueda, L., Moreno, M., Trevisán-Herraz, M., Silla-Castro, J. C., Camafeita, E., Ortega‐Muñoz, M., Bonzón‐Kulichenko, E., et al. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.04.010 · Cited by 40
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 38
Sung, K., Ryu, S., Wild, S. H., & Byrne, C. D. (2015) · Heart · doi:10.1136/heartjnl-2014-306784 · Cited by 37
Kastelein, J. J. P., Duivenvoorden, R., Deanfield, J. E., de Groot, E., Jukema, J. W., Kaski, J. C., Münzel, T. F., Taddei, S., Lehnert, V., Burgess, T., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.536207 · Cited by 35
Self-citationTargeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Self-citationZhang, B., Kawachi, E., Miura, S.-I., Uehara, Y., Matsunaga, A., Kuroki, M., & Saku, K. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1584 · Cited by 40
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism
Schaefer, E. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283612454 · Cited by 34
“001; with 93 versus 59 deaths) in the torcetrapib group versus placebo [12].”
BackgroundCholesteryl ester transfer protein inhibitors: challenges and perspectives
Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 36
“torcetrapib plus atorvastatin or placebo plus atorvastatin [40].”
BackgroundChoi, E., Park, S.-H., Ha, K.-C., Noh, S.-O., Jung, S., Chae, H., Chae, S., & Park, T.-S. (2015) · International Journal of Pharmacology · doi:10.3923/ijp.2015.798.805 · Cited by 35
“…high HDL-cholesterol (Johannsen et al., 2009; Voight et al., 2012) did not correspond to expected outcomes in coronary heart disease risks and drugs that raised HDL-cholesterol failed to reduce CVD events (Barter et al., 2007; The ACCORD Study Group, 2010) or atherosclerosis (Nissen et al., 2007).”
BackgroundResultLipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options
Anagnostis, P. G., Karras, S. Ν., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12903 · Cited by 36
Ganda, A., Yvan‐Charvet, L., Zhang, Y., Lai, E. J., Regunathan-Shenk, R., Hussain, F. N., Avasare, R. S., Chakraborty, B., Febus, A. J., Vernocchi, L., et al. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.05.001 · Cited by 34
Self-citationChristensen, J. J., Ulven, S. M., Retterstøl, K., Narverud, I., Bogsrud, M. P., Henriksen, T., Bollerslev, J., Halvorsen, B. L., Aukrust, P., & Holven, K. B. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.021 · Cited by 35
Zaid, M., Miura, K., Okayama, A., Nakagawa, H., Sakata, K., Saitoh, S., Okuda, N., Yoshita, K., Choudhury, S. R., Rodríguez, B. L., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0341 · Cited by 35
Gorini, S., Marzolla, V., Mammi, C., Armani, A., & Caprio, M. (2018) · Biomolecules · doi:10.3390/biom8030096 · Cited by 40
“Moreover, several clinical studies reveal that circulating aldosterone levels are reliable predictors of cardiovascular ischemia [36,52].”
BackgroundMendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 35
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Schwartz, G. G., Leiter, L. A., Ballantyne, C. M., Barter, P. J., Black, D. M., Kallend, D. G., Laghrissi‐Thode, F., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2204 · Cited by 39
“To date, large outcomes trials have demonstrated no cardiovascular benefit (11-13) or modest cardiovascular”
Self-citationTargeting HDL in tumor microenvironment: New hope for cancer therapy
Zhao, T., Zhu, N., Shi, Y., Wang, Y., Zhang, C., Deng, C., Liao, D., & Li, Q. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30412 · Cited by 40
“Barter et al. Clinical studies have found that after treatment with the CETP inhibitor Torcetrapib, HDL levels have increased by 72%, but cancer patients have a higher mortality rate (Barter et al., 2007).”
BackgroundLipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 46
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Kalaycı, A., Gibson, C. M., Ridker, P. M., Wright, S. D., Kingwell, B. A., Korjian, S., Chi, G., Lee, J., Tricoci, P., Kazmi, S. H. A., et al. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01025-7 · Cited by 38
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 48
“The ILLUMINATE trial of torcetrapib was terminated prematurely after it became evident early in the trial that there was increased incidence of CVD events, by almost 25% ( P = 0.001), despite increasing HDL-C by 72% and simultaneously decreasing LDL-C by 25% [43].”
BackgroundInfluentialLipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 40
Murakami, H., Tanabe, J., Tamasawa, N., Matsumura, K., Yamashita, M., Matsuki, K., Matsui, J., & Suda, T. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.022 · Cited by 35
“[24] Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al.”
BackgroundNanotechnology for synthetic high-density lipoproteins
Luthi, A. J., Patel, P. C., Ko, C. H., Mutharasan, R. K., Mirkin, C. A., & Thaxton, C. S. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.006 · Cited by 35
Peters, S. A. E., den Ruijter, H. M., & Bots, M. L. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11591960-000000000-00000 · Cited by 37
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
van der Tuin, S. J. L., Kühnast, S., Berbée, J. F. P., Verschuren, L., Pieterman, E. J., Havekes, L. M., van der Hoorn, J. W. A., Rensen, P. C. N., Jukema, J. W., Princen, H. M. G., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m057794 · Cited by 34
“These adverse effects were ascribed to an off-target effect ( 11 ) and proinfl am-matory lesions ( 15 ).”
Ng, D. S., Wong, N. C. W., & Hegele, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.238 · Cited by 38
Drug development in the light of translational science: shine or shade?
Wehling, M. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.008 · Cited by 35
Ogita, M., Miyauchi, K., Miyazaki, T., Naito, R., Konishi, H., Tsuboi, S., Dohi, T., Kasai, T., Yokoyama, T., Okazaki, S., et al. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0330-5 · Cited by 36
Kresanov, P., Ahotupa, M. O., Vasankari, T. J., Kaikkonen, J., Kähönen, M. A. P., Lehtimäki, T. J., Viikari, J. S. A., & Raitakari, O. T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.09.023 · Cited by 33
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 35
Karabacak, M., Kahraman, F., Sert, M., Celik, E., Adalı, M. K., & Varol, E. (2015) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.1003595 · Cited by 34
High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes
Barter, P. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.3.169 · Cited by 37
Self-citationChokshi, D. A., Avorn, J., & Kesselheim, A. S. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0843 · Cited by 35
Does high-density lipoprotein protect vascular function in healthy pregnancy?
Sulaiman, W. N. W., CASLAKE, M. J., Delles, C., Karlsson, H., Mulder, M. T., Graham, D., & Freeman, D. J. (2016) · Clinical Science · doi:10.1042/cs20150475 · Cited by 34
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 34
High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes
Davidson, W. S., & SHAH, A. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-55 · Cited by 33
Qie, R., Liu, L., Zhang, D., Han, M., Wang, B., Zhao, Y., Liu, D., Guo, C., Li, Q., Zhou, Q., et al. (2021) · Preventing Chronic Disease · doi:10.5888/pcd18.200278 · Cited by 39
“Among the 22 studies included for the association between HDLC l e v e l a n d I S r i s k i n t h e c u r r e n t m e t a - a n a l y s i s (7,10,11,17,19–21,23,24,41,42,44,45,47,49–52,42,43,45,46,48,50 –53), 16 showed an inverse association (7,10,11,19,20,23,24, 41,42,47,49–52), 10 of which reached a significant lev…”
Holven, K. B., Retterstøl, K., Ueland, T., Ulven, S. M., Nenseter, M. S., Sandvik, M., Narverud, I., Berge, K. E., Ose, L., Aukrust, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078241 · Cited by 39
“In addition, no clinical studies have so far shown reduced morbidity or mortality by increasing the HDL cholesterol levels as the main target [5–6].”
Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials
Verdoia, M., Schaffer, A., Suryapranata, H., & Luca, G. D. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.09.003 · Cited by 33
Martinelli, N., Micaglio, R., Consoli, L., Guarini, P., Grison, E., Pizzolo, F., Friso, S., Trabetti, E., Pignatti, P. F., Corrocher, R., et al. (2011) · Experimental Diabetes Research · doi:10.1155/2012/231502 · Cited by 33
“, blood pressure elevation) have been related to torcetrapib use [31, 32].”
BackgroundRelation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Mathematically modelling the dynamics of cholesterol metabolism and ageing
Morgan, A. E., Mooney, K. M., Wilkinson, S. J., Pickles, N. A., & Auley, M. T. M. (2016) · Biosystems · doi:10.1016/j.biosystems.2016.05.001 · Cited by 35
Intravascular ultrasound and optical coherence tomography imaging of coronary atherosclerosis
Costopoulos, C., Brown, A. J., Teng, Z., Hoole, S. P., West, N. E. J., Samady, H., & Bennett, M. R. (2015) · International journal of cardiac imaging · doi:10.1007/s10554-015-0701-3 · Cited by 33
Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2023) · Critical Care · doi:10.1186/s13054-023-04589-1 · Cited by 32
“However, placebo-controlled randomised trials of CETP inhibitors did not show clear differences in infection rates between arms, despite increases in HDL in the treatment arm [22–24]; that said, these studies were not powered at or aimed to examine risk infection.”
BackgroundHDL and Atherothrombotic Vascular Disease
Annema, W., von Eckardstein, A., & Kovanen, P. T. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_11 · Cited by 36
“The Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial revealed that the combination of atorvastatin with the CETP inhibitor torcetrapib increased HDL cholesterol levels by 72.1 % relative to atorvastatin alone (Barter et al. 2007b).”
BackgroundResultInfluentialThe association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it
Xiong, X., Liu, H., Hua, L., Zhao, H., Wang, D., & Li, Y. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0129-8 · Cited by 33
“All the results might explain why further elevating HDL-c could not increase heart benefits [6, 7], and why there were still residual cardiovascular risks after statin treatment in CHD patients [33, 34].”
BackgroundResult
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.